Gilead Sciences Inc.’s once impermeable defense of its hepatitis C medications has been cracked.
Merck & Co. Inc. won a jury verdict of validity Tuesday on two patents covering the key ingredient in the blockbuster drugs Sovaldi and Harvoni. Gilead isn’t contesting infringement, and the trial proceeded to a damages phase Tuesday afternoon before U.S. District Judge Beth Labson Freeman of the Northern District of California.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
